During the corresponding time, Kura Oncology Inc recorded a revenue increase by 36.54 % year on year, sequentially revenue grew by 14.28 %. While revenue at the Kura Oncology Inc 's corporate clients
Kura Oncology Inc's Comment on Sales, Marketing and Customers
The company serves customers who bill federal programs for products, including manufacturers of drugs, devices, biologics, and medical supplies eligible for payment under Medicare, Medicaid, or the Children’s Health Insurance Program. It also serves healthcare professionals such as physicians—including doctors, dentists, optometrists, podiatrists, and chiropractors—physician assistants, nurse practitioners, and teaching hospitals that receive payments or transfers of value. The markets served encompass federal and state healthcare programs, healthcare service providers, and pharmaceutical distributors, all subject to applicable federal and state laws and regulations.
In the rapidly evolving landscape of oncology treatment, Kura Oncology Inc. in collaboration with Kyowa Kirin Co. is making significant strides with its pioneering drug, ziftomenib. At the prestigious 2025 ASCO Annual Meeting, the announcement of positive pivotal data from the Phase 2 trial of ziftomenib for relapsed or refractory acute myeloid leukemia (AML) with NPM1 mutations marked a watershed moment. With a complete response with complete hematologic recovery (CRCRh) rate of 23%, the data underscore ziftomenib s potential as a novel therapeutic option in a field that has long awaited innovative solutions.The significance of these findings cannot be overstated. AML, a cancer characterized by its aggressi...
Kura Oncology and Kyowa Kirin have entered into a significant global strategic collaboration focused on the development and commercialization of Ziftomenib, a novel therapeutic agent targeting acute leukemias. This collaboration highlights the pharmaceutical industry s increasing emphasis on partnership-driven approaches to enhance drug development and market access. This article outlines the key aspects of the agreement, its implications for the respective companies, and the potential impact on treatment options for patients with acute leukemias. Acute leukemias represent a critical area of unmet medical need in oncology, characterized by rapid progression and often poor prognoses. Ziftomenib, a potent ...
Acute Myeloid Leukemia (AML) presents a significant clinical challenge due to its heterogeneous nature and the varied response to standard treatment protocols. Ziftomenib, a novel therapeutic agent, has garnered attention for its unique mode of action and potential effectiveness when combined with traditional therapies. This article synthesizes findings from recent studies focused on the KOMET-007 trial, which explores the efficacy of Ziftomenib in patients with NPM1-mutations or KMT2A rearrangements when used in conjunction with the established 7+3 regimen. These insights into Ziftomenib s clinical impacts may offer a transformative approach to managing adverse-risk AML.Acute Myeloid Leukemia (AML) is a he...
Unlocking Hope: Kura Oncology s Ziftomenib Phase 1 Breakthrough in Treating Acute Myeloid Leukemia Published in The Lancet Oncology In the evolving landscape of oncology, where innovation and research intertwine, Kura Oncology, Inc. (Nasdaq: KURA) has taken a...
Kura Oncology Inc’s Comment on Sales, Marketing and Customers
The company serves customers who bill federal programs for products, including manufacturers of drugs, devices, biologics, and medical supplies eligible for payment under Medicare, Medicaid, or the Children’s Health Insurance Program. It also serves healthcare professionals such as physicians—including doctors, dentists, optometrists, podiatrists, and chiropractors—physician assistants, nurse practitioners, and teaching hospitals that receive payments or transfers of value. The markets served encompass federal and state healthcare programs, healthcare service providers, and pharmaceutical distributors, all subject to applicable federal and state laws and regulations.
Sources:
Kura Oncology Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Kura Oncology Inc’s corporate clients.
For your research, we’ve provided 9 tables on Kura Oncology Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
71.32 %